"Diagnostics - More important than ever, but there's still a way to go".
Diagnostics are clearly improving and enabling better clinical decisions to be made, especially in oncology where mutation detection is enabling much more personalised approaches to treatment. There is still a long way to go, but combinations of diagnostics tests and technologies (beyond genomics) are giving a more detailed picture on which to base treatment decisions.
Oxford, UK, Friday 15th October: PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.
This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio.
AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.
London, UK, 27 October 2021 – Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited (“Takeda”) for a pre-negotiated upfront payment, as well as potential development and regulatory milestones.
Dr Marcin Mankowski, Co-founder and Deputy Managing Partner of tranScrip, has been appointed tranScrip’s new Managing Partner.
Marcin has been integral to the success of the business over the last decade and is transitioning to the role at an exciting stage of the company’s growth. Underpinned by a recent significant minority investment from Palatine Private Equity Impact Fund, tranScrip is set to rapidly drive revenues with both organic growth and strategic acquisitions.
22nd October 2021 (Rotterdam/Cambridge) – F.INSTITUTE, a Dutch full service finance company for the life sciences, pharma, biotech, deep tech and new energy sector, has recently expanded its portfolio of book-keeping, tax, and CFO services into the UK market. With the appointment of Charles Richmond as their new Director Accounting UK, the company takes the next step towards becoming a dominant player within the international market.
Click here to view the October 2021 edition of Dates for Your Diary
TOKYO and NOTTINGHAM, UK |21 October 2021 - Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc, and We are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, today announce a new collaborative sponsorship and first of its kind initiative to support early stage science ventures.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.